Objectives Understanding the molecular changes in the preclinical synovium is crucial for identifying factors that drive ...

Inovio Pharmaceuticals faces an October 30 PDUFA date for INO-3107 with high regulatory risk and only a 5-7 month cash runway. Read why INO stock is a hold.

While a majority of the therapies currently in development are life-long treatments, Genespire is taking a different approach ...

Astellas Gene Therapies remains intent on treating X-linked Myotubular Myopathy (XLMTM) through a gene therapy—but instead of AAV-based resamirigene bilparvovec (AT132), Astellas is now partnering ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and ...

New genetic evidence reveals unexpected killers behind one of history’s deadliest military disasters.

Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 years (19 months) for placebo (HR=0.23; p=0.008)7-year ...

Vitamin C is a key nutritional component in fruits, yet its concentration often changes dramatically as fruits develop.

Inovio’s upside hinges on INO-3107 for HPV-6/11 RRP with FDA PDUFA Oct 2026, regulatory risk, tight cash, and cheap EV. Check ...

Under the agreement, Bionova will serve as the preferred manufacturing partner for Syenex’s best-in-class delivery platforms.

Plant viruses pose a serious and ongoing threat to global agriculture in tropical to temperate regions. Among the most damaging are begomoviruses, a group of DNA viruses spread by whiteflies that ...

Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...